- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05306834
Stopping Cognitive Decline and Dementia by Fighting Covert Cerebral Small Vessel Disease (SHIVA)
Study Overview
Status
Conditions
Intervention / Treatment
- Procedure: Retinal Imaging
- Genetic: Blood sample
- Procedure: Evaluation of cardiovascular risks
- Procedure: Brain imaging (MRI)
- Other: Cognitive Tests
- Other: Geriatric Depression Scale (GDS)
- Other: Instrumental Activities of Daily Living (IADL)
- Diagnostic test: Unipodal standing test
- Other: Walking speed measurement
Detailed Description
cSVD is by far the most prevalent vascular contributor to cognitive impairment in the population. However, accurate quantitative estimates of the predictive ability of cSVD for dementia risk are lacking. Moreover, stratification of cognitive decline and dementia risk in cSVD patients according to imaging characteristics as well as evidence of coexisting neurodegenerative disease and vascular comorbidity are lacking. Hypertension is the strongest known risk factor for cSVD but there are currently no guidelines for the management of cSVD (or emerging guidelines based on weak evidence, and no specific mechanism-based treatments, leading to empirical and heterogeneous clinical practice, which in most instances consists of ignoring these lesions. This clinical blind spot represents a major "missed opportunity" for the prevention of cognitive decline and dementia.
This study aims to explore the relation of brain and retinal microvasculature image characteristics (imaging biomarkers), as well as molecular biomarkers derived from blood, with presence or absence of extensive cSVD and with cognitive and other clinical characteristics in two groups of 200 patients 60+ years of age. The first group will consist of patients with little or no white matter hyperintensities on brain MRI (no or minor MRI features of cSVD); while the second will include patients with moderate to severe white matter hyperintensities (MRI features of extensive cSVD).
This will create a unique deeply characterized resource for epidemiological and mechanistic investigations of cSVD, which can also serve as a pilot setting to test the trajectories and requirements for individualized patient care of cSVD patients.
The combination of retinal microvascular measurements using innovative multimodal imaging is entirely novel to our knowledge. In the context of the RHU SHIVA program, the same retained imaging protocol will be implemented for 400 young adults, which will provide insight into trajectories of these retinal biomarkers across the adult lifespan).
For the molecular biomarkers allow the validation of genomic, epigenomic, transcriptomic, proteomic, and metabolomic biomarkers for cSVD identified through secondary use of large existing cohort studies in the general population (3C, i-Share cohorts), in persons with memory complaints (MEMENTO cohort), and in collaboration with other cohorts with the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, also as part of the RHU SHIVA program.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Stéphanie DEBETTE, Pr
- Phone Number: +33 5.57.57.16.59
- Email: stephanie.debette@u-bordeaux.fr
Study Locations
-
-
-
Bordeaux, France, 33000
- Recruiting
- Bordeaux Hospital
-
Contact:
- DEBETTE Stéphanie, Pr
-
Paris, France, 75014
- Recruiting
- Broca Hospital
-
Contact:
- HANON Olivier, Pr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
For the extensive cSVD patient group
For the extensive cSVD patient group included in the LEOPOLD trial:
- Patients aged 60 to 88 years,
- Patients included in the LEOPOLD trial and having performed their brain MRI on SIEMENS PRISMA machine
- Being affiliated or beneficiary of the French national health insurance ("sécurité sociale"),
- Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research study).
For the extensive cSVD patient group not included in the LEOPOLD trial:
- Patients aged 60 to 88 years,
- Patients with a cognitive complaint MMSE ≥ 20 performed in the 6 months before inclusion, associated or not with impaired cognitive tests and/or diaognosis of incipient dementia without pronounced cognitive deterioration,
- Patients with a socio-educational level ≥ 3,
- Patients with a moderate to high grade of hypersignals on an MRI OR on an CT scan performed prior inclusion (grades C and D of the modified Scheltens scale or grade 2/3 Fazekas),
- Arterial hypertension defined by a Systolic Blood Pressure (SBP) and / or Diastolic Blood Pressure (DBP) ≥ 140/90 mmHg (according to the definition of the national health authority [HAS]), treated or not, confirmed within the previous 12 months or at the latest on the day of inclusion.
- Being affiliated or beneficiary of the French national health insurance ("sécurité sociale"),
- Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research study)
For the minimal cSVD patient group:
- Patients aged 60 to 88 years,
- Patients with a cognitive complaint (MMSE ≥ 20 performed at the SHIVA inclusion visit or in the 6 monts prior the visit) associated or not with impaired cognitive tests and/or diagnosis of incipient dementia without pronounced cognitive deterioration,
- Patients with little or no white matter hypertensities on brain MRI (grades 0 or 1 on the Fazekas scale); without lacunes or microbleeds,
- Arterial hypertension defined by a Systolic Blood Pressure (SBP) and / or Diastolic Blood Pressure (DBP) ≥ 140/90 mmHg (according to the definition of the national health authority [HAS]), treated or not, confirmed within the previous 12 months or at the latest on the day of inclusion. Blood pressure values for this inclusion criterion can be objectified by several self-measurements performed by the patient at home for 3 days in a sitting or lying position (3 measurements on sitting or lying position and 3 measurements in standing position).
- Being affiliated or beneficiary of the French national health insurance ("sécurité sociale"),
- Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research study
Exclusion Criteria:
For Extensive cSVD patient group :
For the extensive cSVD patient group also included in the LEOPOLD trial:
- patients with severe myopia greater than -6 dioptres
- partients with known allergy to Tropicamide (Mydriaticum®)
- patients with an extensive cataract
- patients with ptosis
For the extensive cSVD patient group not included in the LEOPOLD trial:
- Orthostatic hypotension defined by a decrease of 20 mmHg in SBP and / or 10 mmHg in DBP in a standing position at 3 minutes sought in the previous 3 months or on the day of inclusion,
- Very severe renal impairment (creatinine clearance less than 15 ml / min) on a blood test dating back less than one year,
- Secondary hypertension: renovascular hypertension, primary hyperaldosteronism, pheochromocytoma...
- Contraindication to MRI (presence of a ferromagnetic foreign body, in particular certain intracranial clips, certain heart valves, an intraocular foreign body, metal prosthesis, subject carrying a pacemaker, subject carrying prosthetic heart valves incompatible with MRI. ventricular shunt, claustrophobia),
- Associated severe diseases, with a life expectancy of less than 3 months,
- Physical problems likely to interfere with the feasibility of the tests (sight, hearing, etc.),
- Existence of dementia of which the etiology is distinct from Alzheimer's disease, vascular or mixed dementia
- Persons under tutorship or curatorship,
- Patients with loss of autonomy living in EHPAD (nursing home)
- patients with severe myopia greater than -6 dioptres
- participants with known allergy to Tropicamide (Mydriaticum®)
- patients with an extensive cataract
- patients with ptosis
For the minimal cSVD patient group:
- Orthostatic hypotension defined by a decrease of 20 mmHg in SBP and / or 10 mmHg in DBP in a standing position at 3 minutes sought in the previous 3 months or on the day of inclusion,
- Very severe renal impairment (creatinine clearance less than 15 ml / min) on a blood test dating back less than one year,
- Secondary hypertension: renovascular hypertension, primary hyperaldosteronism, pheochromocytoma...
- Contraindication to MRI (presence of a ferromagnetic foreign body, in particular certain intracranial clips, certain heart valves, an intraocular foreign body, metal prosthesis, subject carrying a pacemaker, subject carrying prosthetic heart valves incompatible with MRI. ventricular shunt, claustrophobia),
- Associated severe diseases, with a life expectancy of less than 3 months,
- Physical problems likely to interfere with the feasibility of the tests (sight, hearing, etc.),
- Existence of dementia of which the etiology is distinct from Alzheimer's disease, vascular or mixed dementia
- Persons under tutorship or curatorship,
- Patients with loss of autonomy living in EHPAD (nursing home)
- Patients with severe myopia greater than -6 dioptries
- Patients with known allergy to Tropicamide (Mydriaticum®)
- Patients with an extensive cataract
- Patients with ptosis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Minimal cSVD patient group
little or no white matter hyperintensities
|
Auto-Refractometry / Adaptative Optics (OA) / Swept Source Optical Coherence Tomography (SS-OCT-A) / Globe Axial length measurements / Color Retinophotography of the retina.
Analyses of molecular biomarkers including
Measurement of blood pressure and arterial stiffness
3DT1 / 3DFLAIR / T2GRE / DTI 15 directions (and B0MAP)
Mini Mental State Examination (MMSE) / Montreal Cognitive Assessment (MoCA) / 16 items Free and Cued Recall (RL/RI 16 items) / Trail Making Test A et B (TMT A et B) / Frontal Assessment Battery (FAB) / Phonemic (letter P) and semantic (animals) verbal fluency tests / Digit Symbol Substitution Test (DSST)
15 items
Instrumental Activities of Daily Living (IADL)
Unipodal standing test
over 5 meters
|
Active Comparator: Extensive cSVD patient group
moderate to severe white matter hyperintensities
|
Auto-Refractometry / Adaptative Optics (OA) / Swept Source Optical Coherence Tomography (SS-OCT-A) / Globe Axial length measurements / Color Retinophotography of the retina.
Analyses of molecular biomarkers including
Measurement of blood pressure and arterial stiffness
3DT1 / 3DFLAIR / T2GRE / DTI 15 directions (and B0MAP)
Mini Mental State Examination (MMSE) / Montreal Cognitive Assessment (MoCA) / 16 items Free and Cued Recall (RL/RI 16 items) / Trail Making Test A et B (TMT A et B) / Frontal Assessment Battery (FAB) / Phonemic (letter P) and semantic (animals) verbal fluency tests / Digit Symbol Substitution Test (DSST)
15 items
Instrumental Activities of Daily Living (IADL)
Unipodal standing test
over 5 meters
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of images and the molecular data
Time Frame: Day 0 and Year 3
|
This comparison should help identify relevant biomarkers to characterize and categorize cSVD.
We will also more broadly look at the association of retinal microvascular markers and molecular biomarkers with all available MRI-markers of cSVD (beyond the presence or absence of extensive white matter hyperintensities that defines the cases and controls).
|
Day 0 and Year 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Degree of association between retinal and brain marker
Time Frame: Day 0, Year 1 and Year 3
|
Degree of association between retinal and brain marker
|
Day 0, Year 1 and Year 3
|
Degree of association between brain, microvascular and retinal marker
Time Frame: Day 0, Year 1, Year 2 and Year 3
|
Data relating to cardiovascular risk factors / clinic data / the results of the cognitive tests, /the results of pan-genomic genotypes obtained by pan-genome genotyping or sequencing (and from blood samples) and other molecular markers
|
Day 0, Year 1, Year 2 and Year 3
|
Correlation between retinal micovascular biomarkers
Time Frame: Day 0, Year 1, Year 2 and Year 3
|
SS-OCT-A (swept source optical coherence tomography angiography) and OA(Adaptive Optic)
|
Day 0, Year 1, Year 2 and Year 3
|
Reproducibility and time course of retinal vascular biomarkers
Time Frame: Between Day 0 and Year 1
|
SS-OCT-A (swept source optical coherence tomography angiography) and OA (Adaptive Optic)
|
Between Day 0 and Year 1
|
Detecting, classifying and quantifying markers of retinal microvascular lesions
Time Frame: up to year 3
|
Performance image acquisition -OCT-A (swept source optical coherence tomography angiography) and OA (Adaptive Optic)
|
up to year 3
|
Comparison of the results in the Shiva study and SHIVA share study
Time Frame: through study completion, an average of 3 year
|
Comparison of the association results and mean distributions observed in SHIVA with those observed in the SHIVA-Share
|
through study completion, an average of 3 year
|
Occurrence of incident stroke, dementia and death during follow-up.
Time Frame: through study completion, an average of 3 year
|
Association of all imaging or molecular biomarkers with the occurrence of incident stroke, dementia and death during follow-up.
|
through study completion, an average of 3 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Olivier HANON, Pr, Assistance Publique - Hôpitaux de Paris
- Study Chair: Marc JOLIOT, Dr, Unité CNRS UMR5296, Groupe d'Imagerie
- Study Chair: Cécile DELCOURT, Dr, Centre INSERM U1219 Bordeaux Population Health
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUBX 2021/22
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
Clinical Trials on Retinal Imaging
-
University of PennsylvaniaNational Eye Institute (NEI)RecruitingAge-related Macular Degeneration | Stargardts | Retinitis Pigmentosa | Choroideremia | Geographic AtrophyUnited States
-
Duke UniversityNational Institute on Aging (NIA)Enrolling by invitationOptical Coherence Tomography of RetinaUnited States
-
Centre Hospitalier National d'Ophtalmologie des...RecruitingStroke | Glaucoma | Hypertension | Diabetes | Retinal Degeneration | Macular Edema | Retinitis Pigmentosa | Trauma | Dry Eye | Keratoconus | Retinal Detachment | Corneal Dystrophy | Vascular Inflammation | Macular Dystrophy | Maculopathy, Age RelatedFrance
-
Universitaire Ziekenhuizen KU LeuvenUnknownDementia | Alzheimer Disease | Mild Cognitive Impairment | Lewy Body Disease | Dementia Alzheimers | Dementia, Lewy BodyBelgium
-
Centre Hospitalier Universitaire DijonRecruitingNephrostomy | Retinal VascularisationFrance
-
Duke UniversityUniversity of Edinburgh in Scotland; Tan Tock Seng Hospital in Singapore; Queens...RecruitingMultiple Sclerosis | Parkinson's Disease | Traumatic Brain Injury | Down Syndrome | Mild Cognitive Impairment | Frontotemporal Dementia | Huntington Disease | Amyotrophic Lateral Sclerosis (ALS) | Alzheimer's Disease | Concussion | Post-Traumatic Stress Disorder | Neuro-Degenerative Disease | Lewy Body Dementia | Normal... and other conditionsUnited States
-
Alexandria UniversityHarvard Medical School (HMS and HSDM); Joslin Diabetes Center; I-care Ophthalmology...RecruitingDiabetic Retinopathy | Diabetic Macular Edema | Retinal DiseaseEgypt
-
Shahid Beheshti University of Medical SciencesUnknownInherited Retinal Dystrophy Primarily Involving Sensory Retina | Inherited Retinal Dystrophy Primarily Involving Retinal Pigment EpitheliumIran, Islamic Republic of
-
Centre Hospitalier Universitaire DijonRecruitingType 1 Diabetes PatientsFrance